Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

TORCH (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus) screening of small for gestational age and intrauterine growth restricted neonates: efficacy study in a single institute in Korea

  • Chung, Mi Hae (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Shin, Chan Ok (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Lee, Juyoung (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • Received : 2017.07.13
  • Accepted : 2017.10.31
  • Published : 2018.04.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Routine screening for toxoplasmosis, rubella, cytomegalovirus (CMV), and herpes simplex virus (TORCH) in intrauterine growth restriction (IUGR) and small for gestational age (SGA) neonates has become a common practice. However, the incidence of TORCH varies across countries, and the cost of TORCH testing may be disadvantageous compared to disease-specific screening. To evaluate the efficacy of TORCH screening, the medical charts of IUGR or SGA neonates born in a single institution in Bucheon, Korea from 2011 to 2015 were reviewed. Methods: The clinical data of the 126 IUGR or SGA neonates were gathered, including gestational age, Apgar scores, neonatal sonographic findings, chromosome study, morbidities, developmental follow-up, and growth catch-up. Maternal factors including underlying maternal disease and fetal sonography were collected, and placental findings were recorded when available. TORCH screening was done using serum IgM, CMV urine culture, quantification of CMV DNA with real-time polymerase chain reaction, and rapid plasma reagin qualitative test for syphilis. Tests were repeated only for those with positive results. Results: Of the 119 TORCH screenings, only one was positive for toxoplasmosis IgM. This result was deemed false positive due to negative IgM on repeated testing and the absence of clinical symptoms. Conclusion: Considering the incidence and risk of TORCH in Korea, the financial burden of TORCH screening, and the single positive TORCH finding in our study, we suggest disease-specific screening based on maternal history and the clinical symptoms of the neonate. Regarding CMV, which may present asymptomatically, universal screening may be appropriate upon cost-benefit analysis.

Keywords

References

  1. Royal College of Obstetricians and Gynecologists. The investigation and management of the small-for-gestational-age fetus (guideline no.31). 2nd ed. London: Royal College of Obstetricians and Gynecologists, 2014.
  2. Martin RJ, Fanaroff AA, Walsh MC. Neonatal-perinatal medicine. 10th ed. Philadelphia (PA): Elsevier/Saunders, 2015.
  3. Sanchez PJ, Demmler-Harrison GJ. Viral infections of the fetus and neonate. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, Kapan SL, editors. Textbook of pediatric infectious diseases. 6th ed. Philadelphia (PA): Saunders Elsevier, 2005:895.
  4. Nahmias AJ, Walls KW, Stewart JA, Herrmann KL, Flynt WJ Jr. The ToRCH complex-perinatal infections associated with toxoplasma and rubella, cytomegol- and herpes simplex viruses. Pediatr Res 1971;5:405-6.
  5. Matthews TG, O'Herlihy C. Significance of raised immunoglobulin M levels in cord blood of small-for-gestational-age infants. Arch Dis Child 1978;53:895-8. https://doi.org/10.1136/adc.53.11.895
  6. de Jong EP, Vossen AC, Walther FJ, Lopriore E. How to use... neonatal TORCH testing. Arch Dis Child Educ Pract Ed 2013;98:93-8. https://doi.org/10.1136/archdischild-2012-303327
  7. Primhak RA, Simpson RM. Screening small for gestational age babies for congenital infection. Clin Pediatr (Phila) 1982;21:417-20. https://doi.org/10.1177/000992288202100705
  8. Khan NA, Kazzi SN. Yield and costs of screening growth-retarded infants for torch infections. Am J Perinatol 2000;17:131-5. https://doi.org/10.1055/s-2000-9288
  9. Wei D, Sardesai SR, Barton L. The C in TORCH: a cost-effective alternative to screening small-for-gestational-age infants. Neonatology 2014;106:24-9. https://doi.org/10.1159/000358867
  10. Al-Hareth Z, Monem F, Abdel Megiud N. Is low birth weight a risk indicator for congenital cytomegalovirus infection? J Infect Dev Ctries 2009;4:44-7.
  11. van der Weiden S, de Jong EP, Te Pas AB, Middeldorp JM, Vossen AC, Rijken M, et al. Is routine TORCH screening and urine CMV culture warranted in small for gestational age neonates? Early Hum Dev 2011;87:103-7. https://doi.org/10.1016/j.earlhumdev.2010.11.005
  12. Yamamoto R, Ishii K, Shimada M, Hayashi S, Hidaka N, Nakayama M, et al. Significance of maternal screening for toxoplasmosis, rubella, cytomegalovirus and herpes simplex virus infection in cases of fetal growth restriction. J Obstet Gynaecol Res 2013;39:653-7. https://doi.org/10.1111/j.1447-0756.2012.02012.x
  13. Committee on Practice Bulletins--Gynecology, American College of Obstetricians and Gynecologists, Washington, DC 20090-6920, USA. Intrauterine growth restriction. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2001;72:85-96. https://doi.org/10.1016/S0020-7292(00)90000-6
  14. Cunningham FG, Leveno KJ, Bloom SL, Spong CY, Dashe JS, Hoffman BL, et al. Williams obstetrics. 24th ed. New York: McGraw-Hill Education, 2014.
  15. Neu N, Duchon J, Zachariah P. TORCH infections. Clin Perinatol 2015;42:77-103. https://doi.org/10.1016/j.clp.2014.11.001
  16. Kliegman RM, Stanton BF, St. Geme JW III, Schor NF, Behrman RE, editors. Nelson textbook of pediatrics. 20th ed. Philadelphia: Elsevier Saunders, 2016.
  17. Wilson CB, Nizet V, Maldonado YA, Remington JS, Klein JO. Infectious disease of the fetus and newborn infant. 8th ed. Philadelphia (PA): Elsevier Saunders, 2016.
  18. Abdel-Fattah SA, Bhat A, Illanes S, Bartha JL, Carrington D. TORCH test for fetal medicine indications: only CMV is necessary in the United Kingdom. Prenat Diagn 2005;25:1028-31. https://doi.org/10.1002/pd.1242
  19. Lopez A, Dietz VJ, Wilson M, Navin TR, Jones JL. Preventing congenital toxoplasmosis. Centers for Disease Control and Prevention. MMWR Recomm Rep 2000;49:57-68.
  20. Centers for Disease Control and Prevention (CDC). Measles, rubella, and congenital rubella syndrome--United States and Mexico, 1997-1999. MMWR Morb Mortal Wkly Rep 2000;49:1048-50, 1059.
  21. Torgerson PR, Mastroiacovo P. The global burden of congenital toxoplasmosis: a systematic review. Bull World Health Organ 2013;91:501-8. https://doi.org/10.2471/BLT.12.111732
  22. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007;17:253-76. https://doi.org/10.1002/rmv.535
  23. Song KJ, Shin JC, Shin HJ, Nam HW. Seroprevalence of toxoplasmosis in Korean pregnant women. Korean J Parasitol 2005;43:69-71. https://doi.org/10.3347/kjp.2005.43.2.69
  24. Han K, Shin DW, Lee TY, Lee YH. Seroprevalence of Toxoplasma gondii infection and risk factors associated with seropositivity of pregnant women in Korea. J Parasitol 2008;94:963-5. https://doi.org/10.1645/GE-1435.1
  25. Yang Z, Cho PY, Ahn SK, Ahn HJ, Kim TS, Chong CK, et al. A surge in the seroprevalence of toxoplasmosis among the residents of islands in Gangwha-gun, Incheon, Korea. Korean J Parasitol 2012;50:191-7. https://doi.org/10.3347/kjp.2012.50.3.191
  26. Lim H, Lee SE, Jung BK, Kim MK, Lee MY, Nam HW, et al. Serologic survey of toxoplasmosis in Seoul and Jeju-do, and a brief review of its seroprevalence in Korea. Korean J Parasitol 2012;50:287-93. https://doi.org/10.3347/kjp.2012.50.4.287
  27. Choe YJ, Lee ST, Song KM, Cho H, Bae GR, Lee JK. Surveillance and control of rubella in the republic of Korea from 2001 to 2009: the necessity for enhanced surveillance to monitor congenital rubella syndrome. Osong Public Health Res Perspect 2010;1:23-8. https://doi.org/10.1016/j.phrp.2010.12.007
  28. Seo S, Cho Y, Park J. Serologic screening of pregnant Korean women for primary human cytomegalovirus infection using IgG avidity test. Korean J Lab Med 2009;29:557-62. https://doi.org/10.3343/kjlm.2009.29.6.557
  29. Cho YH, Kim HO, Lee JB, Lee MG. Syphilis prevalence has rapidly decreased in South Korea. Sex Transm Infect 2003;79:323-4. https://doi.org/10.1136/sti.79.4.323
  30. Kim ID, Chang HS, Hwang KJ. Herpes simplex virus 2 infection rate and necessity of screening during pregnancy: a clinical and seroepidemiologic study. Yonsei Med J 2012;53:401-7. https://doi.org/10.3349/ymj.2012.53.2.401
  31. Pinninti SG, Ross SA, Shimamura M, Novak Z, Palmer AL, Ahmed A, et al. Comparison of saliva PCR assay versus rapid culture for detection of congenital cytomegalovirus infection. Pediatr Infect Dis J 2015;34:536-7. https://doi.org/10.1097/INF.0000000000000609
  32. Rawlinson WD, Boppana SB, Fowler KB, Kimberlin DW, Lazzarotto T, Alain S, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis 2017;17:e177-88. https://doi.org/10.1016/S1473-3099(17)30143-3
  33. Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N Engl J Med 2009;361:1376-85. https://doi.org/10.1056/NEJMra0807633
  34. Nardozza LM, Caetano AC, Zamarian AC, Mazzola JB, Silva CP, Marcal VM, et al. Fetal growth restriction: current knowledge. Arch Gynecol Obstet 2017;295:1061-77. https://doi.org/10.1007/s00404-017-4341-9
  35. Sharma D, Shastri S, Farahbakhsh N, Sharma P. Intrauterine growth restriction - part 1. J Matern Fetal Neonatal Med 2016;29:3977-87. https://doi.org/10.3109/14767058.2016.1152249